Milan Zdravkovic

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

Alan J. Garber, Robert R. Henry, Robert E. Ratner et al. · The Lancet · 2008 · 1.1K citations

Medicine, Endocrinology, Pharmacotherapy +13

Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)

Bernard Zinman, John Gerich, John B. Buse et al. · Diabetes Care · 2009 · 838 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Glucagon-Like Peptide-1 Receptor Agonists Activate Rodent Thyroid C-Cells Causing Calcitonin Release and C-Cell Proliferation

Lotte Bjerre Knudsen, Lars Wichmann Madsen, Søren Andersen et al. · Endocrinology · 2010 · 645 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Tina Vilsbøll, Milan Zdravkovic, T Le-Thi et al. · Diabetes Care · 2007 · 471 citations · Full text

Medicine, Endocrinology, Pharmacology +11

A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir

Johannes Plank, Manfred Bodenlenz, Frank Sinner et al. · Diabetes Care · 2005 · 272 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16